Xintela AB
Xintela AB (publ), a biopharma company, develops medical products in the field of stem cell therapy and targeted cancer therapy. The company's stem cell products include XSTEM, which is in Phase I/IIa clinical development for the treatment of knee osteoarthritis, as well as in clinical study for the treatment of difficult-to-heal leg ulcers, acute respiratory distress syndrome, and other indicati… Read more
Xintela AB (XINT) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.242x
Based on the latest financial reports, Xintela AB (XINT) has a cash flow conversion efficiency ratio of 0.242x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-6.74 Million) by net assets (Skr-27.88 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Xintela AB - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how Xintela AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Xintela AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Xintela AB ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ornsirin Holding Public
BK:ORN
|
-0.075x |
|
NEXTCHIP Co. Ltd
KQ:092600
|
-0.282x |
|
Red Light Holland Corp
OTCQB:TRUFF
|
-0.048x |
|
Geohan Corporation Berhad
KLSE:5345
|
N/A |
|
Dogan Burda Dergi Yayincilik ve Pazarlama AS
IS:DOBUR
|
0.164x |
|
Kantone Holdings Limited
PINK:KTHGF
|
0.031x |
|
An Pha Petroleum Group JSC
VN:ASP
|
N/A |
|
Excel Force MSC Bhd
KLSE:0065
|
0.043x |
Annual Cash Flow Conversion Efficiency for Xintela AB (2013–2024)
The table below shows the annual cash flow conversion efficiency of Xintela AB from 2013 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Skr-5.95 Million | Skr-40.70 Million | 6.841x | +156.41% |
| 2023-12-31 | Skr4.38 Million | Skr-53.12 Million | -12.127x | -77.41% |
| 2022-12-31 | Skr5.78 Million | Skr-39.49 Million | -6.836x | +37.10% |
| 2021-12-31 | Skr3.95 Million | Skr-42.89 Million | -10.867x | -1306.49% |
| 2020-12-31 | Skr27.61 Million | Skr-21.33 Million | -0.773x | +76.68% |
| 2019-12-31 | Skr9.32 Million | Skr-30.89 Million | -3.313x | -377.25% |
| 2018-12-31 | Skr44.95 Million | Skr-31.20 Million | -0.694x | +11.03% |
| 2017-12-31 | Skr18.41 Million | Skr-14.37 Million | -0.780x | +5.90% |
| 2016-12-31 | Skr20.98 Million | Skr-17.40 Million | -0.829x | +35.11% |
| 2015-12-31 | Skr7.46 Million | Skr-9.54 Million | -1.278x | -193.91% |
| 2014-12-31 | Skr9.54 Million | Skr-4.15 Million | -0.435x | +26.64% |
| 2013-12-31 | Skr5.08 Million | Skr-3.01 Million | -0.593x | -- |